Taysha Gene Therapies logo

Taysha Gene Therapies

TSHA | NASDAQ
Chart Builder DCF Calculator
$4.06
-$0.04 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$4.06
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET
-0.98%

Rating

Updated: Nov 16, 2026
41.1
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #492/1021 (Top 48%)

Key Statistics

Market Data

Market Cap $1.65B
1D Range
3.97 4.18
52W Range
3.51 6.98

Valuation (TTM)

PE -9.44
PB 4.62
EV/EBITDA -8.24

Valuation (NTM)

Forward PE N/A
Forward PEG -0.41
Price Target $14.00
Loading financial charts...

Profile

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle in...

Sector Healthcare
Industry Biotechnology
Employees 99
IPO Date Sep 24, 2020
Fiscal Year January - December

Latest News

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript

4 days ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Q3 Earnings Call Highlights

4 days ago · marketbeat.com

Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

4 days ago · globenewswire.com

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

12 days ago · globenewswire.com

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

2 months ago · globenewswire.com

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

2 months ago · seekingalpha.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies Q2 Earnings Call Highlights

3 months ago · marketbeat.com

Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

3 months ago · globenewswire.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential

5 months ago · seekingalpha.com

Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential

Earnings

Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$14.00
Upside
+244.83%
Buy (9)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.